Abstract
Delayed hypersensitivity reactions characterized by rashes occur in patients taking elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta, Vertex Pharmaceuticals, Boston, Massachusetts), a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. ELX/TEZ/IVA was approved in 2019 for patients with cystic fibrosis (CF) greater than or equal to 12 years who carry the Phe508del mutation on at least 1 allele.1 Both ELX and TEZ increase expression of the CFTR protein,1 whereas IVA enhances CFTR channel gating.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
